TheraDiag SA (ALTER):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:TheraDiag SA (ALTER) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C11399
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Theradiag SA (Theradiag), formerly Biomedical Diagnostics SA, is a biotechnology company that develops, manufactures, and markets vitro diagnostic products. The company offers product for the diagnostics of auto-immune diseases, allergies and infectious diseases. It develops product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. Theradiag provides tests using techniques and automatic devices and solutions for high-speed diagnostics. The company also offers multi-parametric monitoring system for treatment of autoimmune diseases by anti-TNF. It provides in-vitro diagnostic products in the fields of auto-immunity, allergies, infectious diseases and, more recently, oncology and molecular biology. The company serves autoimmune disease diagnostic markets. Theradiag is headquartered in Paris, France.

TheraDiag SA (ALTER) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
TheraDiag SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
TheraDiag SA, Medical Equipment Deals By Type, 2012 to YTD 2018 7
TheraDiag SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
TheraDiag SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
TheraDiag SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
TheraDiag SA, Medical Equipment, Deal Details 11
Partnerships 11
Miraca Life Sciences Enters into Licensing Agreement with Theradiag 11
TheraDiag Enters into Agreement with Biogaran 12
Theradiag Enters into Distribution Agreement with HOB Biotech 13
HOB Biotech Enters into Distribution Agreement with Theradiag 14
TheraDiag Enters into Co-Development Agreement with Unicancer and Bordeaux University 15
Theradiag Enters Into Co-Development Agreement With CNRS, IGMM And University of Montpellier 16
TheraDiag Enters Into Distribution Agreement With Luminex For xTAG RVP And xTAG GPP 17
TheraDiag Enters Into Co-Development Agreement With Regional Cancer Institute of Montpellier 18
TheraDiag Enters Into Agreement With Splicos And French National Center for Research 19
Theradiag Enters Into Co-Development Agreement With Sebia For New Diagnostic Kit 20
Equity Offering 21
TheraDiag Raises USD4.5 Million in Private Placement of Shares 21
TheraDiag Raises USD2.78 Million in Private Placement of Shares 22
TheraDiag Raises Funds in IPO of Shares 23
TheraDiag SA – Key Competitors 24
TheraDiag SA – Key Employees 25
TheraDiag SA – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Dec 19, 2017: THERADIAG provides an update on Prestizia and its partnership with HOB Biotech 27
Financial Announcements 28
Sep 19, 2018: Theradiag: 2018 interim results and business update 28
Apr 10, 2018: Theradiag reports its 2017 annual results and sales for first quarter 2018 30
Feb 20, 2018: Theradiag Announces 2017 Annual Sales and Cash Flow at End 2017 32
Oct 26, 2017: Theradiag: Revenues at the end of September 30, 2017 33
Sep 19, 2017: Theradiag: Results and activity for the first half of 2017 Continued improvement in results 34
Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% 36
Apr 27, 2017: THERADIAG Announces First-quarter 2017 Revenues 37
Apr 27, 2017: Theradiag: First-Quarter 2017 Revenues 38
Mar 01, 2017: THERADIAG: Full-year 2016 results 39
Corporate Communications 41
Oct 09, 2018: Evolution of Theradiag’s governance 41
Mar 01, 2017: Appointment of Dominique Costantini and Dominique Takizawa to Theradiag’s Board of Directors 42
Legal and Regulatory 43
Jan 19, 2018: Miraca Life Sciences, Theradiag’s partner in the USA, becomes Inform Diagnostics 43
Product News 44
Mar 28, 2017: Sixth test in Theradiag’s monitoring range launched in the USA 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
TheraDiag SA, Medical Equipment, Key Facts, 2017 2
TheraDiag SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
TheraDiag SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
TheraDiag SA, Medical Equipment Deals By Type, 2012 to YTD 2018 7
TheraDiag SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
TheraDiag SA, Deals By Market, 2012 to YTD 2018 9
TheraDiag SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Miraca Life Sciences Enters into Licensing Agreement with Theradiag 11
TheraDiag Enters into Agreement with Biogaran 12
Theradiag Enters into Distribution Agreement with HOB Biotech 13
HOB Biotech Enters into Distribution Agreement with Theradiag 14
TheraDiag Enters into Co-Development Agreement with Unicancer and Bordeaux University 15
Theradiag Enters Into Co-Development Agreement With CNRS, IGMM And University of Montpellier 16
TheraDiag Enters Into Distribution Agreement With Luminex For xTAG RVP And xTAG GPP 17
TheraDiag Enters Into Co-Development Agreement With Regional Cancer Institute of Montpellier 18
TheraDiag Enters Into Agreement With Splicos And French National Center for Research 19
Theradiag Enters Into Co-Development Agreement With Sebia For New Diagnostic Kit 20
TheraDiag Raises USD4.5 Million in Private Placement of Shares 21
TheraDiag Raises USD2.78 Million in Private Placement of Shares 22
TheraDiag Raises Funds in IPO of Shares 23
TheraDiag SA, Key Competitors 24
TheraDiag SA, Key Employees 25
TheraDiag SA, Subsidiaries 26

List of Figures
TheraDiag SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
TheraDiag SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
TheraDiag SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
TheraDiag SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
TheraDiag SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
TheraDiag SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
TheraDiag SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
TheraDiag SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[TheraDiag SA (ALTER):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Talktalk Telecom Group PLC (TALK):企業の戦略的SWOT分析
    Talktalk Telecom Group PLC (TALK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Hemanext:製薬・医療:M&Aディール及び事業提携情報
    Summary Hemanext, formerly New Health Sciences Inc, is a medical technology company that develops blood storage systems. The company offers an anaerobic storage system that minimizes oxidative damage to red blood cells in storage and delivers physiologic, therapeutic, and fresher red blood cell than …
  • PolyPid Ltd (POLY):製薬・医療:M&Aディール及び事業提携情報
    Summary PolyPid Ltd (PolyPid) is a pharmaceutical company that develops manufactures and commercializes therapies for the treatment of various medical conditions including infection, pain, inflammation and cancer. The company’s pipeline product candidates include D-Plex100, an antibiotic drug reserv …
  • Mega Financial Holding Co., Ltd.:企業の戦略・SWOT・財務情報
    Mega Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mega Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Zafgen Inc (ZFGN):製薬・医療:M&Aディール及び事業提携情報
    Summary Zafgen Inc (Zafgen) is a clinical-stage biopharmaceutical company that develops transformative therapies for patients affected by a range of metabolic diseases. Its pipeline product portfolio includes ZGN-1061, a small molecule MetAP2 inhibitor being developed for patients with type 2 diabet …
  • Iberdrola SA (IBE)-エネルギー分野:企業M&A・提携分析
    Summary Iberdrola, S.A. (Iberdrola) is an electric utility. The company generates, trades, transmits, distributes and markets electricity and gas. It operates hydroelectric, thermal and nuclear power plants in Spain and other countries. The company also involved in the production of electricity from …
  • ZIOPHARM Oncology Inc (ZIOP):製薬・医療:M&Aディール及び事業提携情報
    Summary Ziopharm Oncology Inc (Ziopharm), formerly EasyWeb Inc, is a next-generation immune therapies provider. The company offers controlled IL-12 and t-cell therapy. Its next-generation immune therapie platform provides turning cold tumors hot by activating an immune response and non viral genetic …
  • Colorado Farm Bureau Mutual Insurance Co.:企業の戦略・SWOT・財務情報
    Colorado Farm Bureau Mutual Insurance Co. - Strategy, SWOT and Corporate Finance Report Summary Colorado Farm Bureau Mutual Insurance Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Genoptix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Genoptix Inc (Genoptix) is a healthcare services provider that offers diagnostic solutions. The center offers oncology diagnostics and informatics services. It provides biopharma and healthcare laboratory, discovery, drug development, care and cost development; diagnostics, and patient servi …
  • Devon Energy Corporation (DVN)-石油・ガス分野:企業M&A・提携分析
    Summary Devon Energy Corporation (Devon Energy) is an independent energy company. The company carries out exploration, development, and production of oil, natural gas and natural gas liquids (NGLs). It has its operations in onshore areas of the US and Canada. Devon Energy’s US assets are located in …
  • State Atomic Energy Corporation Rosatom:電力:M&Aディール及び事業提携情報
    Summary State Atomic Energy Corporation Rosatom (ROSATOM) is the Russian Federation national nuclear corporation. It provides a wide range of services in the nuclear production chain, from uranium exploration and mining, uranium conversion and enrichment, nuclear fuel fabrication, mechanical enginee …
  • Dr. Ci:Labo Co., Ltd.:企業の戦略・SWOT・財務情報
    Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • EP Petroecuador:企業の戦略的SWOT分析
    EP Petroecuador - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Glen Dimplex Group:企業の戦略的SWOT分析
    Glen Dimplex Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Sinopec Oilfield Service Corp (600871):企業の財務・戦略的SWOT分析
    Sinopec Oilfield Service Corp (600871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • California Resources Corp (CRC):企業の財務・戦略的SWOT分析
    California Resources Corp (CRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Kotak Wealth Management:企業の戦略・SWOT・財務分析
    Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Condor Petroleum Inc (CPI):石油・ガス:M&Aディール及び事業提携情報
    Summary Condor Petroleum Inc. (Condor) is an independent upstream oil and gas company. The company through its subsidiaries, acquires, explores, produces and markets oil and gas. It has operational presence in Kazakhstan and Turkey. The company operates on the Pre-Caspian basin, a prolific region th …
  • Odonate Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Odonate Therapeutics LLC (Odonate) is a company that develops medicines for the treatment of cancer. It develops best in class medicines that enhance and extend the lives of patients suffering from cancer. Odonate’s lead product candidate, tesetaxel, is a novel orally administered taxane use …
  • IDT Corp (IDT):企業の財務・戦略的SWOT分析
    Summary IDT Corp (IDT) is a telecommunication service provider that offers mobile application development and telecommunication services. The company provides prepaid communication and payment services and international voice termination through its retail and wholesale division. It offers services …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆